Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients.

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F15%3A00084505" target="_blank" >RIV/00216224:14740/15:00084505 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00209805:_____/15:#0000695

Výsledek na webu

<a href="http://bmccancer.biomedcentral.com/articles/10.1186/s12885-015-1752-5" target="_blank" >http://bmccancer.biomedcentral.com/articles/10.1186/s12885-015-1752-5</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s12885-015-1752-5" target="_blank" >10.1186/s12885-015-1752-5</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients.

Popis výsledku v původním jazyce

Background: The anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (moAbs) cetuximab or panitumumab are administered to colorectal cancer (CRC) patients who harbor wild-type RAS proto-oncogenes. However, a percentage of patients do not respond to this treatment. In addition to mutations in the RAS genes,mutations in other genes, such as BRAF, PI3KCA,or PTEN, could be involved in the resistance to anti-EGFR moAb therapy. Methods: In order to develop a comprehensive approach for the detection of mutations and to eventually identify other genes responsible for resistance to anti-EGFR moAbs, we investigated a panel of 21 genes by parallel sequencing on the Ion Torrent Personal Genome Machine platform. We sequenced 65 CRCs that were treatedwith cetuximab or panitumumab. Among these, 37 samples were responsive and 28 were resistant.

Název v anglickém jazyce

Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients.

Popis výsledku anglicky

Background: The anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (moAbs) cetuximab or panitumumab are administered to colorectal cancer (CRC) patients who harbor wild-type RAS proto-oncogenes. However, a percentage of patients do not respond to this treatment. In addition to mutations in the RAS genes,mutations in other genes, such as BRAF, PI3KCA,or PTEN, could be involved in the resistance to anti-EGFR moAb therapy. Methods: In order to develop a comprehensive approach for the detection of mutations and to eventually identify other genes responsible for resistance to anti-EGFR moAbs, we investigated a panel of 21 genes by parallel sequencing on the Ion Torrent Personal Genome Machine platform. We sequenced 65 CRCs that were treatedwith cetuximab or panitumumab. Among these, 37 samples were responsive and 28 were resistant.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

BMC Cancer

ISSN

1471-2407

e-ISSN

—

Svazek periodika

15

Číslo periodika v rámci svazku

October

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

11

Strana od-do

—

Kód UT WoS článku

000363502400001

EID výsledku v databázi Scopus

—